- Therapeutic Cataract & Refractive
- Lens Technology
- Glasses
- Ptosis
- AMD
- COVID-19
- DME
- Ocular Surface Disease
- Optic Relief
- Geographic Atrophy
- Cornea
- Conjunctivitis
- LASIK
- Myopia
- Presbyopia
- Allergy
- Nutrition
- Pediatrics
- Retina
- Cataract
- Contact Lenses
- Lid and Lash
- Dry Eye
- Glaucoma
- Refractive Surgery
- Comanagement
- Blepharitis
- OCT
- Patient Care
- Diabetic Eye Disease
- Technology
Bepotastine besilate ophthalmic solution 1.5% clears the hurdle for allergic ocular itching
The FDA Dermatologic and Ophthalmic Drugs Advisory Committee has recommended the approval of bepotastine besilate ophthalmic solution 1.5% (Bepreve, ISTA Pharmaceuticals) for treating ocular itching associated with allergic conjunctivitis.
Key Points
Irvine, CA-The FDA Dermatologic and Ophthalmic Drugs Advisory Committee has recommended the approval of bepotastine besilate ophthalmic solution 1.5% (Bepreve, ISTA Pharmaceuticals) for treating ocular itching associated with allergic conjunctivitis.
The FDA still is required to approve the application and has set a date of Sept. 12 to take further action on the drug.
Bepotastine besilate is an eye-drop treatment that acts as a non-sedating, highly selective antagonist of the histamine receptor. It has been approved in Japan since 2000 to treat allergic rhinitis and urticaria/pruritus.
